{"type":"rich","version":"1.0","title":"Pharmaceutical Executive Daily: The Medicare GLP-1 Bridge","description":"In today's Pharmaceutical Executive Daily, AlzeCure Pharma announces a collaboration with QuantumCell ApS worth more than $2.2 billion for global rights to its Neurostore platform including Alzheimer's candidate ACD856, the Medicare GLP-1 Bridge launches today, giving eligible Medicare Part D beneficiaries access to Wegovy, Foundayo, and Zepbound for a $50 monthly copay through the end of 2027, and Pharmaceutical Executive speaks with Ryan Last of Troutman Pepper Locke on the limits of targeted pharmaceutical tariffs as a reshoring tool and why thin margins on many generic products complicate the policy's effectiveness.","author_name":"Pharmaceutical Executive","author_url":"https://audioboom.com/channels/5120049-pharmaceutical-executive","provider_name":"Audioboom","provider_url":"https://audioboom.com","width":480,"height":95,"thumbnail_url":"https://audioboom.com/i/43723512/600x600/c","thumbnail_width":600,"thumbnail_height":600,"html":""}